SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma

• M. Provencio Pulla ^[1] ; J. Alfaro Lizaso ^[7] ; L. de la Cruz Merino ^[2] ; J. Gumá i Padró ^[8] ; C. Quero Blanco ^[9] ; J. Gómez Codina ^[10] ; M. Llanos Muñoz ^[3] ; N. Martinez Banaclocha ^[4] ; D. Rodriguez Abreu ^[5] ; A. Rueda Domínguez ^[6]
  1. [1] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
  2. [2] Hospital Universitario Virgen Macarena

     Hospital Universitario Virgen Macarena

     Sevilla, España

     
  3. [3] Hospital Universitario de Canarias

     Hospital Universitario de Canarias

     San Cristóbal de La Laguna, España

     
  4. [4] Hospital General Universitario de Elche

     Hospital General Universitario de Elche

     Elche, España

     
  5. [5] Complejo Hospitalario Universitario Insular - Materno Infantil de Canarias

     Complejo Hospitalario Universitario Insular - Materno Infantil de Canarias

     Gran Canaria, España

     
  6. [6] Hospital Costa Del Sol

     Hospital Costa Del Sol

     Marbella, España

     
  7. [7] Instituto Oncológico de Guipúzcoa
  8. [8] Hospital Universitari de Sant Joan de Reus
  9. [9] Complejo Hospitalario Regional y Virgen de la Victoria
  10. [10] Hospital Universitari i Politècnic la Fe

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 17, Nº. 12, 2015, págs. 1014-1019
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Follicular non-Hodgkin’s lymphoma (FL) is a nodal B lymphoid malignancy that originates from the germinal center of a lymph node. FL is the second most frequent lymphoma subtype. The course of the disease is usually characterised by a typically indolent clinical course, with a median survival rate of 8–10 years, although most patients relapse after treatment. Diagnosis should always be based on a surgical specimen like an excisional node lymph biopsy. The first-line treatment of FL will depend of extension disease, tumour burden, patient symptoms, performance status and also patient decision. The addition of rituximab to conventional chemotherapy has improved ORR, PFS and OS. As first line in patients that need treatment, a combination of chemotherapy with rituximab induction followed by 2 years of rituximab maintenance is the best option. High-dose chemotherapy with autologous stem-cell transplantation in first line has not shown improvement and is not recommended as first-line therapy. Before any treatment decision in relapsed patients, a repeat biopsy is mandatory to rule out a transformation into large cell aggressive lymphoma. Standard treatment is controversial, depends on the efficacy of prior treatment, duration of the time-to-relapse, patient’s age and histological findings at relapse.